{
    "id": 23344,
    "cites": 14,
    "cited_by": 5,
    "reference": [
        "Davis, Steven J. Regulatory complexity and policy uncertainty: headwinds of our own making. Becker Friedman Institute for Research in Economics Working Paper (2015).",
        "DiMasi, Joseph A., and Grabowski, Henry G. The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics 28, no. 4\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u00905 (2007): 469-479.",
        "DiMasi, J. A., Grabowski, H. G., and Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. Medford, MA: Tufts Center for the Study of Drug Development (2014).",
        "DiMasi, Joseph A., Hansen, Ronald W., Grabowski, Henry G., and Lasagna, Louis. Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10, no. 2 (1991): 107-142.",
        "DiMasi, Joseph A., Reichert, Janice M., Feldman, Lanna, and Malins, Ashley. Clinical approval success rates for investigational cancer drugs. Clinical Pharmacology & Therapeutics 94, no. 3 (2013): 329-335.",
        "Fama, Eugene F., and French, Kenneth R. Common risk factors in the returns on stocks and bonds. Journal of Financial Economics 33, no. 1 (1993): 3-56.",
        "Fernandez, Jose-Maria, Stein, Roger M., and Lo, Andrew W. Commercializing biomedical research through securitization techniques. Nature Biotechnology 30, no. 10 (2012): 964-975.",
        "Koijen, R., Philipson, T., and Uhlig, H. (2016), \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financial Health Economics\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, Econometrica 84, no 11 :195\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c242 Philipson, Tomas, \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Hedging Pipeline Risk in Pharma: FDA Swaps and Annuities.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Milken Institute (March 2015a).",
        "Philipson, Tomas. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Saving Lives through Financial Innovation: FDA Swaps and Annuities\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forbes, (March 2015b).",
        "Thakor, Richard T., Anaya, Nicholas, Zhang, Yuwei, Vilanilam, Christian, and Lo, Andrew W. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Financial Risk and Return in the Biotech and Pharmaceutical Industries from 1930 to 2015\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Working Paper, Sloan School of Management, Massachusetts Institute of Technology, 2016.",
        "Thakor, Richard T., and Andrew W. Lo. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Competition and R&D financing decisions: Theory and evidence from the biopharmaceutical industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d No. w20903. National Bureau of Economic Research, 2015.",
        "March 2017 FDA Hedges Page 41 of 41 Thakor, Richard T., and Lo, Andrew W. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimal Financing for R&D-intensive Firms\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d.",
        "Thomas, David W., Burns, Justin, Audette, John, Carroll, Adam, Dow-Hygelund, Corey, and Hay, Michael. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Clinical Development Success Rates\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d. Biotechnology Innovation Organization (BIO), 2016.",
        "March 2017 Appendix: FDA Hedges Page A\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c1 of 9"
    ]
}